Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUTURE MEDICINE LTD
Autores
ARAUJO, Luiz H
FERREIRA, Carlos Gil
BALDOTTO, Clarissa S.
MATHIAS, Clarissa
COUDRY, Renata
Citação
FUTURE ONCOLOGY, v.17, n.2, p.205-214, 2020
Resumo
The objective of this review is to address the barriers limiting access to next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) for metastatic nonsquamous non-small cell lung cancer in Brazil and to propose its implementation in practice. A selected panel of lung cancer experts was provided with relevant prompts to address at a conference; a paper was then compiled on the topic. The authors propose specific and realistic recommendations for implementing access to ctDNA NGS. Further, the authors address all barriers and impediments mentioned within this review. There is a great need to increase ctDNA NGS for cancer care in Brazil. Adapting the current cancer testing framework is essential to expanding the use of this tool.
Palavras-chave
Brazil, circulating tumor DNA, metastatic, next-generation sequencing, NGS, non-small cell lung cancer, NSCLC
Referências
- [Anonymous], 2020, LUNG CANC
- Araujo LH, 2019, J BRAS EC SAUDE, V11, P221
- Araujo LH, 2018, J BRAS PNEUMOL, V44, P55, DOI [10.1590/S1806-37562017000000135, 10.1590/s1806-37562017000000135]
- Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
- Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
- Costa G, 2016, LUNG CANCER, V97, P66, DOI 10.1016/j.lungcan.2016.04.019
- Fares Charlene M, 2019, Am Soc Clin Oncol Educ Book, V39, P147, DOI 10.1200/EDBK_240837
- Ferreira CG, 2018, J THORAC ONCOL, V13, pS714, DOI 10.1016/j.jtho.2018.08.1183
- Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
- Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101
- Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167
- Heitzer E, 2019, NAT REV GENET, V20, P71, DOI 10.1038/s41576-018-0071-5
- Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8
- INCA - Instituto Nacional de Cancer, 2020, INC CANC BRAZ
- INCA - Instituto Nacional de Cancer, 2019, CANC PULM
- Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007
- Lindeman NI, 2018, J THORAC ONCOL, V13, P323, DOI 10.1016/j.jtho.2017.12.001
- Liu LP, 2018, GENE CHROMOSOME CANC, V57, P211, DOI 10.1002/gcc.22522
- Malta Deborah Carvalho, 2007, J. bras. pneumol., V33, P536, DOI 10.1590/S1806-37132007000500008
- Mathias C, 2020, J THORAC ONCOL, V15, P170, DOI 10.1016/j.jtho.2019.07.028
- Mazieres J, 2019, ANN ONCOL, V30, P1321, DOI 10.1093/annonc/mdz167
- Merker JD, 2018, J CLIN ONCOL, V36, P1631, DOI 10.1200/JCO.2017.76.8671
- Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7
- Neder L, 2019, PRECISION MED, V4, P1
- Oxnard GR, 2020, ANN ONCOL, V31, P507, DOI 10.1016/j.annonc.2020.01.013
- Palacio S, 2019, ONCOLOGIST, V24, pE137, DOI 10.1634/theoncologist.2018-0254
- Passiglia F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30780-4
- Pinsolle J, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00233
- Pinto MT, 2015, CAD SAUDE PUBLICA, V31, DOI 10.1590/0102-311X00192013
- Rolfo C, 2018, J THORAC ONCOL, V13, P1248, DOI 10.1016/j.jtho.2018.05.030
- Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84
- Santos M, 2019, LANCET ONCOL, V20, P20, DOI 10.1016/S1470-2045(18)30822-2
- Schoenfeld AJ, 2019, ANN ONCOL, V30, P839, DOI 10.1093/annonc/mdz077
- Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088
- Suh JH, 2016, ONCOLOGIST, V21, P684, DOI 10.1634/theoncologist.2016-0030
- Thompson JC, 2016, CLIN CANCER RES, V22, P5772, DOI 10.1158/1078-0432.CCR-16-1231